NewsHK
The rare-disease genetic medicine sector is pressing into a new commercial and pipeline cycle, with approved gene therapies requiring broader distribution reach and next-generation siRNA programs advancing toward proof-of-concept data.
Against that backdrop, Sarepta Therapeutics (NASDAQ: SRPT) confirmed on July 27, 2026 that Michael Severino, M.D.
will become chief executive officer effective July 28, succeeding Doug Ingram, who is retiring after leading the company through its most consequential regulatory period.
A succession built around pipeline execution Severino brings more than 25 years of biopharmaceutical experience.
Keep reading